Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Sells $76,718.56 in Stock

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insider Neal Flomenberg sold 70,384 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $1.09, for a total value of $76,718.56. Following the completion of the transaction, the insider now owns 3,898,828 shares of the company’s stock, valued at $4,249,722.52. The trade was a 1.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Neal Flomenberg also recently made the following trade(s):

• On Thursday, March 6th, Neal Flomenberg sold 88,519 shares of Tevogen Bio stock. The stock was sold at an average price of $1.10, for a total value of $97,370.90.
• On Tuesday, March 4th, Neal Flomenberg sold 14,639 shares of Tevogen Bio stock. The stock was sold at an average price of $1.28, for a total transaction of $18,737.92.

Tevogen Bio Stock Up 0.9 %

NASDAQ TVGN opened at $1.07 on Wednesday. The firm’s fifty day moving average price is $1.36 and its two-hundred day moving average price is $1.17. Tevogen Bio Holdings Inc. has a fifty-two week low of $0.26 and a fifty-two week high of $6.95.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Tevogen Bio in a research report on Tuesday.

Hedge Funds Weigh In On Tevogen Bio

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its position in Tevogen Bio by 31.2% in the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock worth $465,000 after purchasing an additional 107,566 shares in the last quarter. HGC Investment Management Inc. purchased a new stake in Tevogen Bio in the 3rd quarter worth approximately $82,000. Northern Trust Corp lifted its stake in Tevogen Bio by 13.0% in the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock worth $122,000 after purchasing an additional 13,595 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Tevogen Bio during the 4th quarter valued at $55,000. Finally, Barclays PLC raised its position in shares of Tevogen Bio by 39.2% during the 4th quarter. Barclays PLC now owns 45,600 shares of the company’s stock valued at $48,000 after buying an additional 12,847 shares in the last quarter.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.